Organon & Co. (NYSE:OGN) Hits New 1-Year High – Here’s What Happened

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high on Thursday . The stock traded as high as $13.49 and last traded at $13.4850, with a volume of 68157 shares trading hands. The stock had previously closed at $13.48.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Organon & Co. currently has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Price Performance

The company’s 50-day moving average price is $12.84 and its 200-day moving average price is $9.31. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of 14.52, a PEG ratio of 1.25 and a beta of 1.55.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.02 EPS. On average, equities research analysts forecast that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Insider Buying and Selling

In other news, SVP Lynette Holzbaur purchased 26,448 shares of the stock in a transaction on Wednesday, May 6th. The stock was bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.62% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Foster Dykema Cabot & Partners LLC acquired a new position in Organon & Co. in the third quarter valued at approximately $29,000. Farther Finance Advisors LLC increased its stake in Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. in the 4th quarter valued at about $44,000. Kestra Advisory Services LLC purchased a new stake in shares of Organon & Co. during the fourth quarter worth approximately $47,000. Finally, WNY Asset Management LLC purchased a new position in Organon & Co. during the 1st quarter worth $64,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.